

5 2-PYRIDINONE DERIVATIVES, HAVING HIV INHIBITING PROPERTIESField of the invention

[0001] The present invention relates to 2-pyridinone derivatives, in particular 5-ethyl-6-methyl-2-pyridinone derivatives, that inhibit HIV, especially human
10 immunodeficiency virus type 1 (HIV-1) replication. They are therefore of interest in the treatment of Acquired Immune Deficiency Syndrome (AIDS). The present invention further relates to the synthesis of said compounds and their use, alone or in combination with other pharmaceutical and/or
15 therapeutic agents, in the treatment of viral infectious diseases like AIDS, especially viral infections by HIV-1.

Background of the invention

[0002] Human Immunodeficiency Virus (HIV) is the
20 causative agent of AIDS. Two main forms of this virus (HIV-1 and HIV-2) have been identified. HIV-0 is a subtype of HIV-1. HIV-1, HIV-2 and HIV-0 are all causative agents of AIDS, of which HIV-1 is the most common one. As a retrovirus from the lentivirus family, HIV has its genome
25 in the form of single-stranded RNA.

[0003] An essential step of HIV life cycle is therefore the reverse transcription of this single stranded RNA into double-stranded DNA. This process is catalyzed by a virally encoded enzyme known as reverse transcriptase.
30 Numerous reverse transcriptase inhibitors have been used as

antiretroviral agents. Most of them can be classified either as nucleoside reverse transcriptase inhibitors (NRTIs), also known as nucleoside analogues, or as non-nucleoside reverse transcriptase inhibitors (NNRTIs) that
5 bind at an allosteric site (referred to as "TIBO site") some 10 Å from the catalytic site of the reverse transcriptase (RT) as described De Clercq E. et al (New developments in anti-HIV chemotherapy, Biochem. Biophys Acta 2002, 258-275). Most NNRTIs display marked selectivity
10 for HIV-1 inhibition.

State of the art

[0004] European patent application EP0462800 describes a first series of pyridinone derivatives and their use in
15 the treatment of HIV-related diseases.

[0005] European patent application EP0462808 discloses a series of pyridinone derivatives that are structurally related to those of EP0462800 and also find their use in the treatment of HIV-related diseases.

20 [0006] European patent application EP0481802 describes the preparation of 2-pyridinones and 2-pyridinethiones and their use in the treatment of HIV-related diseases.

[0007] International patent application WO97/05113 discloses the preparation of 4-aryl-thio-pyridinones and
25 their use in the treatment of HIV-related diseases.

[0008] International patent application WO02/08226 discloses tricyclic 2-pyridinone compounds which are useful as inhibitors of HIV reverse transcriptase.

[0009] Published US patent application US2003125340
30 discloses 3-(Amino-or aminoalkyl) pyridinone derivatives and their use for the treatment of HIV related diseases.

[0010] International patent application WO99/55676 discloses the preparation of 3-amino- and 3-aminoalkyl-

pyridinone and pyridinethione derivatives and their use in the treatment of HIV-related diseases.

[0011] International patent application WO02/24650 and European patent application EP 1 318 995 disclose another
5 series of pyridinone and pyridinethione derivatives displaying HIV inhibiting properties.

[0012] The Publication of Dolle et al. (J.Med.Chem. 1995, 38, 4679-4686) discloses a series of 4-aryl-thio-pyridinones.

10 [0013] The present invention provides still further antiviral agents with excellent activity against HIV-1 infections.

Aims of the invention

15 [0014] The present invention aims to provide new antiviral agents that are able to prevent, inhibit and/or suppress viral infections and that show especially improved inhibitory action towards Human Immunodeficiency Virus type 1 (HIV-1) replication (reversible or irreversible
20 inhibitors active against wild-type and mutant strains).

[0015] In particular, the present invention aims to provide such compounds which are non-nucleoside reverse transcriptase inhibitors (NNRTIs), able to block HIV-1 replication, and which do not require metabolic activation
25 (e.g. phosphorylation) to be active.

[0016] A preferred aim of the present invention is to obtain such compounds that are irreversible inhibitors, especially compounds that bind irreversibly to the allosteric site of HIV-1 reverse transcriptase (RT).

30 [0017] A further aim of the present invention is to provide such compounds, which can be used in the prevention, suppression and/or the treatment of viral infections, either as pure compounds, as pharmaceutically acceptable salts or as prodrug thereof and/or as ingredient

of a pharmaceutical composition, possibly in combination with other antiviral active agents and/or immunomodulators.


[0018] A last aim of the present invention is to provide methods of synthesis for such compounds and to
5 provide compounds obtainable by said methods.

Summary of the invention

[0019] One aspect of the invention concerns the antiviral compounds of claim 1, preferably antiviral
10 compounds that block the allosteric site of HIV-1 reverse transcriptase, preferably by an irreversible binding (e.g. through a covalent bond). Irreversible antiviral compounds allow a definitive deactivation of this HIV-1 enzyme and therefore a definitive blocking of HIV-1 replication.

15 [0020] Advantageously, these compounds may also be effective in blocking replication of resistant HIV-1 strains that comprise one or more mutations in the (wild type) RT sequence, which may render these strains resistant to existing antiviral compounds.

20 [0021] In particular, the present invention is related to new non-nucleoside reverse transcriptase inhibitor compounds (NNRTIs), which display HIV-1 inhibitory properties, having the general formula I:




25

(formula I)

wherein


X = O, S, NH, C=O, (C_nH_{2n}), (C_nH_{2n})O, O(C_nH_{2n}), (C_nH_{2n})S, S(C_nH_{2n}) with n = 1-4



with n, m = 0 - 8

Ar = Aromatic ring selected from : phenyl, pyridyl, thiazolyl, furanyl, thiophenyl, benzofuranyl, benzothiophenyl, benzothiazolyl, imidazolyl, indolyl, each optionally substituted with up to 4 substituents selected from : halo, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ hydroxyalkyl, C₁₋₄ alkylamino, amino, C₁₋₄ aminoalkyl, C₁₋₄ alkylcarbonyl, C₁₋₄ dialkylamino, azido

Y = H, halo, alkylamino, dialkylamino, nitrile, hydroxy, C₁₋₆ alkyloxycarbonyl, C₁₋₆ alkylcarbonyloxy, C₅₋₇ cycloalkyl optionally substituted with up to 4 substituents selected from : halo, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ hydroxyalkyl, C₁₋₄ alkylamino, amino, C₁₋₄ aminoalkyl, C₁₋₄ alkylcarbonyl, C₁₋₄ dialkylamino, azido, nitrile; or Y can be :



or Y = alkyl, amino, nitro.

R2 = C₇₋₉ cycloalkyl;

C₅₋₈ cycloalkyl substituted with up to 4 substituents;

C₅₋₈cycloalkenyl optionally substituted with up to 4 substituents;


C₅₋₈aliphatic heterocycle optionally substituted with up to 4 substituents;

C₆₋₉bridged cycloalkyl optionally substituted with up to 4 substituents;


C₆₋₉bridged cycloalkenyl optionally substituted with up to 4 substituents;

substituents selected from :

halo, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ hydroxyalkyl, C₁₋₄ alkylamino, amino, C₁₋₄ aminoalkyl, C₁₋₄ alkylcarbonyl, C₁₋₄ dialkylamino, azido, CN;



Or R2 can be :




n, m = 0 - 8

[0022] Preferably, in such compounds according to formula 1, X = O or


X =



- 5 and/or R1 is one selected from the group consisting of CO₂Et, CH₂OH, NO₂, NH₂, CH₂SCOMe, CH₂S(CH₂)₂OH, CH₂S(CH₂)₂OCOCH₂Cl, NMe₂, CH₂N₃, Me, Et,




and




- 10 for ethyl. , with Me standing for methyl and Et standing

[0023] According to an embodiment of the invention, the compound is a compound according to general formula (I) with X and R1 as defined above, and with R2 selected from the group consisting of



- 15 n, m = 0 - 8

[0024] Most preferably, R 2 of said compound is



with n=0 - 8, preferably n= 0, 1, 2, 3 or 4, more preferably n = 0, 1, or 2 and most preferably n = 1.

- 20 [0025] A most preferred compound is one according to formula I, in which R2 is as given in formula XII, with n

preferably = 1, and in which X = O and R1 preferably CO₂Et (CO₂Et).

[0026] According to another embodiment, the compound is one according to general formula I in which

R2 = C₇₋₉ cycloalkyl;

C₅₋₈ cycloalkyl substituted with up to 4 substituents;

5


C₅₋₈ aliphatic heterocycle optionally substituted with up to 4 substituents;

C₆₋₉ bridged cycloalkyl optionally substituted with up to 4 substituents;

substituents selected from :

halo, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ hydroxyalkyl, C₁₋₄ alkylamino, amino, C₁₋₄ aminoalkyl, C₁₋₄ alkylcarbonyl, C₁₋₄ dialkylamino, azido, CN;

or substituents selected from:



10 [0027] According to another embodiment, the compound is one according to general formula I in which R2 is selected from the group consisting of


C₅₋₈cycloalkenyl optionally substituted with up to 4 substituents;

C₆₋₉bridged cycloalkenyl optionally substituted with up to 4 substituents;

substituents selected from :

halo, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ hydroxyalkyl, C₁₋₄ alkylamino, amino, C₁₋₄ aminoalkyl, C₁₋₄ alkylcarbonyl, C₁₋₄ dialkylamino, azido, CN;

or substituents selected from:



5.

[0028] Preferred compounds are those referred to as M18, Z12, Z25, Z30, Z32, Z33, Z37, Z37inv, Z53, Z54, Z55, Z57, Z45inv, Z91inv, Z96inv, Z114, Z121, Z122, Z150, Z153, Z154 and Z167 (see *infra*, e.g. table 2 wherein X, R1 and R2 are specified for each of said compounds). An aspect of the invention relates to each of these compounds.

[0029] The present invention is also related to pharmaceutically acceptable salts or prodrugs of said compounds as well as to a pharmaceutical composition comprising at least one of the different compounds according to the invention (in pure form and/or as acceptable salt and/or as prodrug) and further an adequate pharmaceutical carrier and/or diluent. The compounds

15

according to the invention may be used in combination with any other suitable (known or yet unknown) antiviral compounds, anti-infective agents, immunomodulators, antibiotics and/or vaccines.

5 [0030] Said pharmaceutical composition can find advantageous and efficient use in the prevention, treatment and/or the suppression of viral infections by Human Immunodeficiency Virus type 1 (HIV-1).

[0031] Another aspect of the present invention is
10 related to the use of any of the compounds according to the invention (in pure form and/or as salt and/or as prodrug) or the pharmaceutical composition according to the invention as a medicament and/or for the manufacture of a medicament to treat, suppress and/or prevent viral
15 infections induced by Human Immunodeficiency Virus type 1 (HIV-1).

[0032] A further aspect of the present invention is related to the preparation method of said compounds as described in detail hereafter.

20 [0033] A last aspect of the present invention concerns a method for obtaining an irreversible anti-HIV-1 compound, which method comprises the steps of:

- selecting an anti-HIV-1 compound, preferably a NNRTI, that interacts with a binding site of an HIV-1 enzyme,
- 25 - introducing a chemical modification in the structure of said anti-HIV-1 compound that allows the formation of at least one covalent bond between the compound and an amino acid of said HIV-1 enzyme.

[0034] The obtained (obtainable) irreversible anti-
30 HIV-1 compounds, through the formation of said at least one covalent bond, can bind irreversibly to said HIV-1 enzyme, which preferably is a reverse transcriptase (RT).

[0035] Irreversible anti-HIV-1 compound allow a definitive deactivation of the HIV enzyme such as the RT.

[0036] Advantageously, an equimolar quantity of said compounds is sufficient for complete deactivation unlike for irreversible compounds, which may be metabolized and/or may be excreted in living cells.

5 [0037] A preferred binding site is the allosteric binding site (TIBO site) of HIV-1 reverse transcriptase.

[0038] The chemical modification may imply the introduction of an alkylating function.

[0039] Preferably, this chemical modification is the
10 introduction of a chemical function or moiety at position 3 (thus at the level of R1) in a compound according to formula 1.

[0040] This may be the introduction of a $\text{NH-COCH}_2\text{Halo}$ moiety at an existing side group, preferably one at
15 position 3. A preferred halogen is Cl.

[0041] Most preferably, the final group (after modification, id est after introduction of the moiety) is one that accords to the formula $\text{CH}_2\text{X}(\text{CH}_2)_n\text{XCO}(\text{CH}_2)_m\text{Halo}$ (formula XIII), wherein X is S or O, n is comprised between
20 1 and 8 and m is comprised between 1 and 8. A preferred halogen is Cl.

[0042] A preferred final group is $\text{CH}_2\text{S}(\text{CH}_2)_2\text{OCOCH}_2\text{Halo}$. Again, a preferred halogen is Cl.

[0043] A most preferred final side group (after
25 modification) is $\text{CH}_2\text{S}(\text{CH}_2)_2\text{OCOCH}_2\text{Cl}$.

[0044] The above method allows to transform potent (but reversible) anti-HIV-1 compounds, like the NNRTI of the invention, into even more potent compounds by making them irreversible binders (binding compounds) and blockers
30 (blocking agents).

[0045] The following examples and specific embodiments are intended for illustration purposes only, and should not be construed as limiting the scope of the invention in any way.

Brief description of the Figures

[0046] The Figure 1 represents the synthesis of ethyl
4-[(3,5-dimethylcyclohexyl)oxy]-5-ethyl-6-methyl-pyridine-
5 2(1H)-one-3-carboxylate (compound Z37).

[0047] The Figure 2A and 2B represent respectively the
X-ray structure of compound Z37A and Z37inv.

[0048] The Figure 3 represents the synthesis of 4-
(cycloheptyloxy)-3-(hydroxymethyl)-5-ethyl-6-methylpyridin-
10 2(1H)-one (compound Z32).

[0049] The Figure 4 represents the synthesis of [4-
(cycloheptyloxy)-5-ethyl-6-methyl-2-oxo-1,2-dihydropyridin-
3-yl]methyl chloroacetate (compound Z33).

[0050] The Figure 5 represents the synthesis of 2-
15 (dimethylamino)ethyl 4-[(3,5-dimethylcyclohexyl)oxy]-5-
ethyl-6-methyl-pyridine-2(1H)-one-3-carboxylate (compound
Z53).

[0051] The Figure 6 represents the synthesis of ethyl
5-ethyl-6-methyl-4-[(3-methylbut-2-enoyl)oxy]-2-oxo-1,2-
20 dihydropyridine-3-carboxylate (compound M18).

[0052] The Figure 7 represents the synthesis of 3-
nitro-5-ethyl-6-methyl-4-[(3,5-dimethylcyclohexyl)oxy]
pyridine-2(1H)-one (compound Z91inv).

[0053] The Figure 8 represents the synthesis of 5-
25 ethyl-6-methyl-4-[(3,5-dimethylcyclohexyl)oxy]- 3-
-{[(2-hydroxyethyl)sulfanyl]methyl}pyridine-2(1H)-one (compound
Z121).

[0054] The Figure 9 represents the synthesis of 3-
(dimethylamino)-5-ethyl-6-methyl-4-[(3,5-
30 dimethylcyclohexyl)oxy] pyridine-2(1H)-one (compound Z150).

[0055] The Figure 10 represents general formula I.

Detailed description of the invention

[0056] Compounds of general formula I (see above) that are described in the present invention behave either as reversible reverse transcriptase inhibitors or as irreversible reverse transcriptase inhibitors. The following two-step mechanism is thought to be involved in irreversible inhibition:

1. reversible binding to the allosteric site (TIBO site) of HIV-1 reverse transcriptase, and
- 10 2. formation of a covalent bond with a reactive amino-acid of the TIBO site, leading to irreversible inhibition


[0057] Of particular interest are compounds of formula I with a specific substitution in position 4 of the pyridinone ring. Such compounds display an excellent antiviral activity against HIV-1. A particular example hereof is for instance compound Z150, which bears a 3,5-dimethylcyclohexyl moiety as R2 (see general formula above).

20 [0058] Some of the compounds according to the present invention were found to exhibit an excellent antiviral activity against HIV-1 mutant strains that are resistant to one or more antiviral agents active against HIV-1 such as commonly applied NNRTIs like Nevirapine.

25 Examples

Example 1: Synthesis of ethyl 4-[(3,5-dimethylcyclohexyl)oxy]-5-ethyl-6-methyl-pyridine-2(1H)-one-3-carboxylate (compound Z37)

[0059] Compound Z37 which corresponds to formula II



(formula II)

was synthesized, following a three-step protocol, as described below and as illustrated in Figure 1.

Step 1

5 [0060] ethyl 4-hydroxy 5-ethyl-6-methyl-pyridine-2(1H)-one-3-carboxylate (**B0**) was synthesized as described by E. Bisagni and al. (J.Med.Chem. 1995, 38, 4679-4686). Then, benzyl bromide (1.8g, 10.5 mmol) was added to a stirred suspension of silver carbonate (1.41g, 5.1mmol) and **B0** 10 (2.25g, 10mmol). The mixture was heated (50°C) overnight then cooled and filtered over celite 521 (Aldrich). The solvent was evaporated and the crude product purified using a silica gel column (e.g. a 60Å/0.040-0.063mm ROCC column; eluent: pentane/dichloromethane, 70/30 v/v%), to give 15 intermediate **A** (2.6g, 83% yield).

Step 2

[0061] In a second step, Diisopropyl azodicarboxylate (DIAD) (0.804g, 4 mmol) was added drop wise at room temperature to a solution of intermediate **A** (0.63 g, 2 20 mmol), triphenylphosphine ($P\Phi_3$) (1.048g, 4 mmol) and 3,5-dimethylcyclohexanol (0.512g, 4 mmol) in THF (20ml). After stirring overnight, the THF was evaporated and the residue was suspended in a mixture of hexane and diethyl ether (50:50 v/v%). The precipitate was filtered off and the 25 organic layer was evaporated. The residue obtained was purified using a silica gel column (e.g. a 60Å/0.040-0.063mm ROCC column; eluent: pentane/dichloromethane, 50/50 v/v%), to give intermediate **B** (0.595 g, 70% yield).

Step 3

[0062] In a third step, Pd/C 10% (w/w%) (0.160g) was added to a solution of intermediate B (0.360g, 0.89 mmol) in cyclohexane (4ml) and diisopropyl ether (12 ml). The mixture was heated overnight at 70°C. The precipitate was then filtered off and the organic solvents were evaporated. The product was purified with a silica gel column (e.g. a 60Å/0.040-0.063mm ROCC column; eluent: dichloromethane/ethanol, 95/05 v/v%) to give product Z37 as a mixture of stereoisomers (0.238 g, 80% yield, mp (melting point) for the mixture of stereoisomers = 108°C).

[0063] The major isomer of the mixture, Z37A (70%) was purified by chiral HPLC (e.g. using a DAICEL chiralpak AD 4,6/250mm column; eluent: hexane/isopropanol 95/05 v/v%). (mp= 122°C).

[0064] A nuclear magnetic resonance (NMR) ¹H profile was obtained using an Ex 90 FT NMR spectrometer (Jeol) and gave the following information for compound Z37A:

NMR ¹H for Z37A: δ 13 (s, 1H), 4.7 (m, 1H), 4.4 (q, 2H), 2.4 (q, 2H), 2.25 (s, 3H), 2.15-1.6 (m, 8H), 1.35 (t, 3H), 1.0 (t, 3H), 0.85 (d, 6H)

[0065] A diastereoisomeric form of Z37A (Z37inv) was obtained by a stereoselective double Mitsunobu reaction (mp= 158°C) (David L. Hugues 1992, "The mitsunobu reaction", Organic Reaction, 42, 335). Its antiviral activity was found to be higher than the activity observed for either Z37A or the mixture of stereoisomers (see infra).

[0066] The stereochemistry of compounds Z37A and Z37inv was checked by X-Ray diffraction using a Enraf-Nonius CAD-4 apparatus (Brucker). The X-Ray diffraction structures of both compounds are given in Figures 2 A and B respectively. The crystal data of both compounds, as well


as the specific data collection information and applied refinement conditions, are summarized in Table 1.

Table 1: Crystal data, data collection and refinement information for compounds Z37A and Z37inv (symbols used are standard IUPAC symbols well known in the art)

	Z37A	Z37inv
Crystal Data		
Formula	$C_{19}H_{29}NO_4$	$C_{19}H_{29}NO_4$
MW	335.43	335.43
System, space group	Triclinic, P-1	Monoclinic, P21/c
a (Å)	8.518(1)	13.488(3)
b (Å)	9.220(2)	9.064(2)
c (Å)	13.436(1)	16.584(1)
α (°)	88.906(6)	90.0
β (°)	82.053(4)	110.617(16)
γ (°)	66.369(7)	90.0
V (Å ³)	956.7(2)	1897.6(6)
Z	2	4
D _x (Mg m ⁻³)	1.164	1.174
Radiation	Cu K α	Cu K α
μ (mm ⁻¹)	0.651	0.066
T (K)	293(2)	293(2)
Crystal	Platelet, colourless	Platelet, colourless
Crystal size	0.34 x 0.30 x 0.13	0.45 x 0.34 x 0.25
Data collection		
Diffractometer	Enraf-Nonius CAD-4	Enraf-Nonius CAD-4
Scan	$\theta/2\theta$	$\theta/2\theta$
Absorption correction	Analytical $T_{\min}=0.809$, $T_{\max}=0.920$	None
Measured reflections	4012	4075
Independent reflections	3764	3907
Reflections with $I > 2 \sigma(I)$	3067	3223
R_{int}	0.0137	0.0967
θ_{max}	71.97	74.98
h	-9 -> 10	0 -> 16
k	0 -> 11	0 -> 11
l	-16 -> 16	-20 -> 19
Refinement		
Refinement on	F^2	F^2
$R[F^2 > 2 \sigma(F^2)]$	0.0526	0.0825
wR(F^2)	0.1759	0.2150
S	1.462	1.689
Number of reflections	3764	3907
Number of parameters	223	221
$(\Delta/\sigma)_{\text{max}}$	0.013	0.001
$\Delta\rho_{\text{max}}$	0.289	0.421
$\Delta\rho_{\text{min}}$	-0.299	-0.335

Example 2: Synthesis of 4-(cycloheptyloxy)-3-(hydroxymethyl)-5-ethyl-6-methylpyridin-2(1H)-one (compound Z32)

[0067] Compound Z32 which corresponds to formula III



(formula III)

5

was synthesized, following a three-step protocol, as described below and as illustrated in Figure 3.

Step 1

10 [0068] In a first step, Diisopropyl azodicarboxylate (DIAD) (0.804g, 4 mmol) was added drop wise at room temperature to a solution of above-described intermediate A (0.63 g, 2 mmol), triphenylphosphine ($P\Phi_3$) (1.052g, 4 mmol) and cycloheptanol (0.456g, 4 mmol) in THF (20ml). After
15 stirring overnight, the THF was evaporated and the residue was suspended in a mixture of hexane and diethyl ether (50:50 v/v%). The precipitate was filtered off and the organic layer was evaporated. The residue obtained was purified using a silica gel column (e.g. a 60Å/0.040-
20 0.063mm ROCC column; eluent: pentane/dichloromethane, 50/50 v/v%), to give intermediate C (0.575 g, 70% yield).

Step 2

[0069] In a second step, Red-Al (2.3 ml, 7.6 mmol) was suspended in benzene (10 ml). Intermediate C (1.77g, 4.3
25 mmol) was added to this solution, at 0°C. The mixture was heated at 75°C for 2 hours and then cooled again at 0°C. After addition of a solution of 20% sulphuric acid, the

aqueous layer was extracted with dichloromethane. The organic extracts were collected and washed with brine.

[0070] The crude product was chromatographed on silica gel column (e.g. a 60Å/0.040-0.063mm ROCC column; 5 eluent: dichloromethane/pentane, 50/50 v/v%) to afford intermediate D (1.507 g, 95% yield).

Step 3

[0071] In a third step, Intermediate D (1.5g, 4 mmol) was then dissolved in a mixture of acetonitrile (10 ml) and 10 dimethyl sulfide (2 ml). Trifluoroacetic acid (1ml) was then added to this mixture, at 0°C. After stirring at room temperature for 3 hours, the solvents were evaporated. The residue was dissolved in dichloromethane and washed with a solution of saturated NaHCO₃.


15 [0072] After drying with MgSO₄ and evaporation of the solvent; recrystallisation from ethyl acetate/hexane gave pure product Z32 as white crystals (mp = 146°C)

[0073] A nuclear magnetic resonance (NMR) 1H profile was obtained using an Ex 90 FT NMR spectrometer (Jeol) and 20 gave the following information for compound Z32:

NMR 1H for Z32: δ 13 (s, 1H), 4.6 (s, 2H), 4.1 (m, 1H), 2.44 (q, 2H), 2.31 (s, 3H), 1.7 (m, 12H), 1.1 (t, 3H)

Example 3: Synthesis of [4-(cycloheptyloxy)-5-ethyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl]methyl chloroacetate
25 (compound Z33)

[0074] Compound Z33 which corresponds to formula IV



(formula IV)

was synthesized from compound Z32 as described below and as illustrated in Figure 4. Compound Z32 (165 mg, 0.6 mmol) was dissolved in dichloromethane (2ml) and pyridine (50 μ l).

5 Chloroacetyl chloride (50 μ l) was added to this mixture cooled at 0°C. After stirring for 3 hours at 0°C, HCl (1ml, 1N) and dichloromethane (10ml) were added to this solution.

[0075] The organic layer was washed with a saturated NaCl solution and the crude product purified using a silica


10 gel column (eluent: MeOH/CH₂Cl₂, 1/9) to give the crystalline product Z33 (0.160 g, Yield: 75%, mp = 123°C).

[0076] A nuclear magnetic resonance (NMR) ¹H profile was obtained using an Ex 90 FT NMR spectrometer (Jeol) and gave the following information for compound Z33:

15 NMR ¹H for Z33: δ .13 (s, 1H), 5.2 (s, 2H), 4.2 (m, 1H), 4.0 (s, 2H), 2.5 (m, 2H), 2.3 (s, 3H), 1.7 (m, 12H), 1.1 (m, 3H)

Example 4: Synthesis of 2-(dimethylamino)ethyl 4-[(3,5-dimethylcyclohexyl)oxy]-5-ethyl-6-methyl-pyridine-2(1H)-one-3-carboxylate (compound Z53)

[0077] Compound **Z53** which corresponds to formula V



(formula V)

5

was synthesized from compound **Z37** as described below and as illustrated in Figure 5. To a solution of **Z37** (0.167g, 0.5 mmol) in N,N-diethylethanolamine (3ml) was added a catalytic amount of tetraisopropyl titanate (c.a. 30 mg).

10 The mixture was stirred overnight at 110°C.

[0078] The solvent was then evaporated under vacuum and the residue was extracted with dichloromethane. The crude product was purified with a silica gel column (eluent: dichloromethane/ethanol, 90/10) to give product


15 **Z53** (0.121 g, 60% yield, oil).

[0079] A nuclear magnetic resonance (NMR) ¹H profile was obtained using an Ex 90 FT NMR spectrometer (Jeol) and gave the following information for compound **Z53**:

NMR ¹H for **Z53**: δ 12.8 (s, 1H), 4.7 (m, 1H), 4.3 (t, 2H),
20 2.9-2.4 (m, 6H), 2.3 (s, 3H), 2.1-1.4 (m, 8H), 1.25-0.7 (m, 17H).

Example 5: Synthesis of ethyl 5-ethyl-6-methyl-4-[(3-methylbut-2-enoyl)oxy]-2-oxo-1,2-dihydropyridine-3-carboxylate (compound M18)

[0080] Compound M18 which corresponds to formula VI




5 was synthesized as described below and as illustrated in Figure 6. Intermediate B0 (0.338g, 1.5 mmol) was dissolved in dichloromethane (10 ml) and pyridine (1 ml). 3,3-dimethyl acryloyl chloride (0.360g, 3.0 mmol) was added to
10 this solution at 0°C and the solution was stirred overnight. The solvents were then removed in vacuo. Purification by silica gel chromatography (e.g. a 60Å/0.040-0.063mm ROCC column; eluent: ethanol/dichloromethane, 98/02 v/v%) gave product M18
15 (0.270g, 60% yield, mp = 166°C).

[0081] A nuclear magnetic resonance (NMR) 1H profile was obtained using an Ex 90 FT NMR spectrometer (Jeol) and gave the following information for compound M18:
NMR 1H for M18: δ 13 (s, 1H), 5.9 (s, 1H), 4.2 (q, 2H), 2.5
20 (m, 2H), 2.3 (s, 3H), 2.2 (s, 3H), 2.0 (s, 3H), 1.3 (t, 3H), 1.1 (t, 3H)

[0082] Compounds Z12, Z25, Z30, Z54 and Z55 were synthesized in a similar way as compound Z37. The protocol
25 is similar except for the alcohol used in the second step, which is 2-chlorocyclohexanol for Z12, cycloheptanol for Z25, 3-methylcyclohexanol for Z30, cyclooctanol for Z54 and 4-ethylcyclohexanol for Z55.

Example 6: Synthesis of 3-nitro-5-ethyl-6-methyl-4-[(3,5-dimethylcyclohexyl)oxy] pyridine-2(1H)-one (compound Z91inv)


[0083] Compound **Z91inv**, which corresponds to formula I below, was synthesized in a similar way as compound **Z37** as illustrated in Figure 7.



(formula VIII)

10 Example 7: Synthesis of 5-ethyl-6-methyl-4-[(3,5-dimethylcyclohexyl)oxy]-3-([(2-hydroxyethyl)sulfanyl]methyl)pyridine-2(1H)-one (compound Z121)

[0084] Compound **Z121**, which corresponds to formula IX below, was synthesized following a three-step protocol,
15 as described below and as illustrated in Figure 8.



(formula IX)

Step 1

[0085] Intermediate **E** was synthesized from **B** in a
20 similar way as compound **Z32** (step 2).

Step 2

[0086] Thionyl chloride (0.5ml, 6.8 mmol) was added to a solution of intermediate E (0.383g, 1mmol) in benzene (15ml). The mixture was heated at reflux for 4 hours. After evaporation of the solvent, the residue was precipitated in 5 30 ml of hexane giving intermediate F (0.155g, 50% yield). Intermediate F was unstable and must be used immediately for the next step.


Step 3

10 [0087] The mixture of intermediate F (0.155g, 0.5mmol), 2-mercaptoethanol (0.156g, 2mmol) and triethylamine (0.2ml) in dichloromethane (10ml) was stirred at room temperature for 24 hours. After evaporation of the solvent, the residue was extracted by dichloromethane and 15 neutralised by hydrochloric acid (0.1M). The residue was purified on silica gel column (e.g. a 60Å/0.040-0.063mm ROCC column ; eluent: dichloromethane/ethanol, 95/5 v/v%) to give compound Z121 (0.088g, 50% yield).

[0088] NMR ¹H for Z121: δ 1.3 (s, 1H), 5.2 (s, 1H), 20 4.2 (m, 1H), 4 (m, 4H), 2.95 (m, 2H), 2.4 (q, 2H), 2.25 (s, 3H), 2-1 (m, 11H), 0.9 (d, 6H)

Example 8: Synthesis of 3-(dimethylamino)-5-ethyl-6-methyl-4-[(3,5-dimethylcyclohexyl)oxy]pyridine-2(1H)-one (compound
25 Z150).

[0089] Compound Z150, which corresponds to formula X below, was synthesized, following a two-step protocol, as described below and as illustrated in Figure 9.



(formula X)

Z150

Step 1

[0090] A mixture of Z91inv (0.550g, 1.786mmol) and tin(II)chloride dihydrate (2g, 8.88mmol) in ethylacetate (30ml) was heated under reflux for 3 hours. After cooling
5 at 0°C and adding ice water, the suspension was basified with a solution of 10% sodium carbonate. The filtrate was evaporated and the residue was purified on silica gel column (e.g. a 60Å/0.040-0.063mm ROCC column; eluent: dichloromethane /ethanol, 95/5 v/v%) giving compound Z96inv
10 (0.397g, 80% yield).

[0091] NMR 1H for Z96inv: δ 12.6 (s, 1H), 4.2 (m, 1H), 3.9 (m, 2H), 2.4 (q, 2H), 2.25 (s, 3H), 2-1 (m, 11H), 0.9 (d, 6H)

Step 2

15 [0092] A mixture of Z96inv (0.150g, 0.54mmol), aqueous formaldehyde 37% (0.8ml, 10mmol), sodium cyanoborohydride (0.150g, 2.4mmol), acetic acid (0.2ml, 3.4mmol) and acetonitrile (10ml) was stirred at room temperature for 24 hours. After evaporation of the solvent,
20 the residue was extracted with dichloromethane (3x30ml) and neutralised by aqueous sodium hydroxide 10%. The residue was purified on silica gel column (e.g. a 60Å/0.040-0.063mm ROCC column; eluent: dichloromethane/ethanol, 95/5 v/v%) giving compound Z150 (0.077g, 50% yield).











25 [0093] NMR 1H for Z150: δ 12.2 (s, 1H), 4.8 (m, 1H), 2.8 (s, 6H), 2.4 (q, 2H), 2.25 (s, 3H), 2-1 (m, 11H), 0.9 (d, 6H)












[0094] Compound Z45inv was synthesized from intermediate E in a similar way as compound Z32 (third
30 step).




[0095] Compound Z122 was synthesized from Z121 in a similar way as compound Z33.

[0096] Table 2 provides information on the structure and physico-chemical properties of specific compounds according to the invention, such as the nature of the side groups R1 and R2 and of the spacer X, the melting point of the compound and its molecular weight.

Table 2: Structure and physico-chemical properties of specific compounds (N°) according to the invention

N°	X	R1	R2	mp (°C)	Molecular Weight
M18	O	CO ₂ Et		166	Calculated: 307 Measured: 307
Z12	O	CO ₂ Et		oil	Calculated: 341 Measured: 341
Z25	O	CO ₂ Et		112	Calculated: 321 Measured: 321
Z30	O	CO ₂ Et		oil	Calculated: 321 Measured: 321
Z32	O	CH ₂ OH		146	Calculated: 279 Measured: 279
Z33	O			123	Calculated: 355 Measured: 355
Z37	O	CO ₂ Et		108	Calculated: 335 Measured: 335
Z53	O			oil	Calculated: 406 Measured: 406

Z54	O	CO ₂ Et		104	Calculated: 335 Measured: 335
Z55	O	CO ₂ Et		100	Calculated: 335 Measured: 335
Z57		CO ₂ Et		oil	Calculated: 335 Measured: 335
Z45inv	O	CH ₂ OH		157-158	Calculated: 293 Measured: 293
Z91inv	O	NO ₂		206-207	Calculated: 308 Measured: 308
Z96inv	O	NH ₂		251-252	Calculated: 278 Measured: 278
Z114	O	CH ₂ SCOMe		140-143	Calculated: 351 Measured: 351
Z121	O	CH ₂ S(CH ₂) ₂ OH		133-134	Calculated: 353 Measured: 353
Z122	O	CH ₂ S(CH ₂) ₂ OCOCH ₂ Cl		Oil	Calculated: 429 Measured: 429
Z150	O	NMe ₂		129-130	Calculated: 306 Measured: 306

Z153	O	CH ₂ N ₃		138-140	Calculated: 318 Measured: 318
Z154	O	Me		149-150	Calculated: 277 Measured: 277
Z167	O	Et		160-161	Calculated: 291 Measured: 291

Oil = viscous liquid formation

[0097] The following examples demonstrate that the compounds of the present invention are very efficient
5 NNRTIs with HIV-1 inhibiting activity.

[0098] This is illustrated via *in vitro* reverse transcriptase assays and via anti-HIV assays using P4, TMZ-bl and MT4 cell lines and PBMC. Both the P4 and TMZ-bl cell lines contain in their genomes the bacterial LacZ gene
10 under the transcriptional control of HIV-1 LTR elements. In these cells, the expression level of the β -galactosidase gene is proportional to the viral replication. The P4 cells express at their surface the CD4 protein, used as a receptor by HIV. The TMZ-bl cells express at their surface
15 both the CD4 and CCR5 proteins. CCR5 is used as a co-receptor by HIV-1. The presence of both the receptor and co-receptor at their cell surface make the TMZ-bl cells much more sensitive to infection by the virus compared to the P4 cells. The MT-4 cell line is also widely used to
20 asses the efficacy of drugs against HIV. The MT-4 cell line is derived from CD4⁺ T-lymphocytes chronically infected with Human T-cell Lymphotropic Virus-1 (HTLV-1). These cells rapidly die upon infection by HIV. In this system cellular viability is inversely proportional to viral
25 replication. Peripheral Blood Mononuclear Cells (PBMCs)

isolated from the blood of non infected donor contain primary CD4⁺ T-lymphocytes. These cells are one of the main targets of HIV in infected individuals. In this system viral replication is measured by quantifying the viral capsid protein p24 in supernatants of infected cells cultures.

[0099] For the *in vitro* inhibition studies of the HIV-1 reverse transcriptase activity, stock solutions of the compounds of the present invention were prepared in dimethyl sulfoxide at a final concentration of 10mM and kept at room temperature. Nevirapine was purchased from Boehringer Ingelheim. Efavirenz was received from the NIH AIDS Research and Reference Reagent Program.

[0100] For the antiviral and the cytotoxicity assays, the drugs were diluted in complete DMEM medium. In these experiments, drugs were diluted in triplicate wells in a 96-well plate in six, 5 fold serial dilutions.

Example 9: Effect of the compounds according to the invention on the HIV-1 *in vitro* reverse transcriptase activity

HIV-1 reverse transcriptase activity:

[0101] *In vitro* inhibition studies used a fixed-time assay for HIV-1 reverse transcriptase RNA dependent DNA polymerase activity. RT was purchased from Calbiochem (ref CAL382129-500). One unit of RT corresponds to the amount of enzyme which incorporates one nanomole of [³H]TTP in 10 minutes at 37°C.

[0102] Assays were performed in a final volume of 50μl. The mixture contained 0.125 units of RT, 10 mM MgCl₂, 2mM DTT, 50mM Tris pH 8.3, 50mM KCl, 1μg/μl BSA, 0.01% triton X100, 20 μg/ml (0.4 A260/ml) poly(rC)-oligo(dG)₁₂₋₁₈, 1μCi [³H]dGTP and 1μl of the inhibitor (dissolved in

dimethyl sulfoxide, DMSO). Reaction mixtures were incubated at 37°C for 10 min. The incorporation rate was determined by a standard trichloroacetic acid precipitation procedure (adapted from *Current protocols in molecular biology*. Eds Wiley, MGH Harvard medical school) and liquid scintillation counting using a Wallac scintillation counter.

[0103] Results for some of the compounds according to the invention are summarized in Table 3. The *in vitro* activity of the compounds, at a final concentration of 10 μ M, on the reverse transcriptase (RT) activity of HIV-1 is derivable from the relative (%) reduction in RT activity. Hereby, the RT activity in the absence of any of the compounds is set at 100%.

[0104] From table 3 it is evident that all the compound tested were able to reduce the *in vitro* RT activity by at least about 30%. Most of the compounds tested were able to reduce the *in vitro* activity by at least 50 to 60%. The most active compounds (Z91inv, Z114, Z150, Z153...) reduced the activity by 99-100 %. This reduction of RT activity is better than the one observed with nevirapine and comparable to the one observed with efavirenz, both common NNRTI.

Table 3: *In vitro* residual RT activity after addition of some compounds (N°) belonging to the invention. Comparison with Nevirapine and Efavirenz, two common RT inhibitors

N°	Relative (%) RT activity <i>in vitro</i> (compound added at 10 μ M)
M18	70.8
Z12	63.7
Z25	34.6
Z30	22.0
Z32	44.0
Z33	42.0
Z37	8.3
Z37A	7.6
Z37B	5.6

Z37inv	5.5
Z45inv	12.1
Z53	34.3
Z54	24
Z55	40.3
Z57	ND
Z91inv	0
Z96inv	25.4
Z114	0
Z121	1.4
Z122	39.1
Z150	0.9
Z153	0.7
Z154	1.6
Nevirapine	16.7
Efavirenz	1.7

[0105] *In vitro* tests also show that inhibition of RT by the compound Z122 increases with respect to the time of incubation. Z122 seems to be an irreversible inhibitor of the reverse transcriptase. In agreement with this hypothesis, we observed in the same experiments that the activity of the alcohol derivative Z121, which lacks the alkylating function, is independent of the preincubation time with the RT.

10 [0106] After the preincubation, the unbound Z122 and the RT were separated using a micro-spin desalting column. Following this treatment, we did not observe any increase in the RT activity. However, the same experiment performed with the Z121 molecule resulted in a significant increase
15 in the RT activity following the separation step. These data are consistent with the formation of a covalent link between the Z122 compound and the reverse transcriptase.

20 Example 10: Anti-HIV-1 activity (EC50 value expressed in μM) on P4, TZM-bl, MT4 cell lines and PBMC and cytotoxicity (CC50 value expressed in μM) of some of the compounds according to the invention

Production of Viral stocks:

[0107] Wurzburg Jurkat T cells (subclone JR) were transfected with 10 μ g of the circularly permuted infectious molecular clone HIV_{NL4-3} (Adachi et al., 1986. J. Virol, 59 (2), p284-291). Two days later, co-cultivation with SupT1 cells (a human T-cell lymphoma cell line) was initiated to facilitate rapid production of progeny virions. Production of virus was measured by using the *Innotest HIV Antigen mAb p24* kit (Innogenetics). At the peak of production cultures were harvested and filtered. The virus stocks were stored at -80°C until used.

[0108] In order to introduce mutation(s) at the level of the pol gene coding for the RT in the pNL4-3 plasmid containing the complete viral genome (Adachi et al., 1986. J. Virol., Vol. 59 p284-291) we used the "Quick change mutagenesis kit" (Stratagene). The following mutations were separately introduced in pNL4-3: L100I, K103N, V108I, Y181C, Y188C, and the double mutations K103N/V108I. These mutations were chosen because of the resistance that they confer to existing NNRTI. The production procedure of the mutant viral stocks is identical to the one described above.

P4 Cell line:

[0109] Anti-HIV activity and cytotoxicity of the compounds were tested on a P4 cell line. The P4 cell line (Clavel & Charneau, 1994. J. Virol., Vol.68 p1179-1185) was provided by Dr. François Clavel (Unité de recherche antivirale de l'hôpital Xavier Bichat Paris: Inserm). The P4 cells were cultured in complete DMEM medium supplemented with 10% fetal bovine serum (FBS), 0.5 % of Penicillin/Streptomycin and G418 at 0.5 mg/ml. Exponentially growing cells were trypsinized, centrifuged and split twice weekly at $5 \cdot 10^4$ cells/ml.

TZM-bl cell line:

[0110] Anti-HIV activity and cytotoxicity of the compounds were tested on the TZM-bl cell line. The TZM-bl cell line (Wei et al. 2002. Antimicrob. Agents Chemother. Vol. 46, p1896-1905) was received from the NIH AIDS Research and Reference Reagent Program. These cells were cultured in complete DMEM medium supplemented with 10% fetal bovine serum (FBS), and 1% Penicillin/Streptomycin. Exponentially growing cells were trypsinized, centrifuged and split twice weekly at 5×10^4 cells/ml.

MT-4 cell line:

[0111] Anti-HIV activity of the compounds was tested on MT-4 cell line. The MT-4 cell line (Larder et al. 1989. Sciences, Vol. 243 p1731) was received from the NIH AIDS Research and Reference Reagent Program. These cells were cultured in RPMI medium supplemented with 10% fetal bovine serum (FBS), and 1% Penicillin/Streptomycin. The cultures were split regularly to keep cells densities between 0.3 to 1.2×10^6 cells/ml.

Peripheral Blood Mononuclear Cells:

[0112] Anti-HIV activity of the compounds was tested on Peripheral Blood Mononuclear Cells (PBMCs). These cells were separated from the blood of healthy donor using established procedures. PBMCs were cultured in RPMI medium supplemented with 10% fetal bovine serum (FBS), 1% Penicillin/Streptomycin and 20 U/ml of Interleukin-2.

Cytotoxicity of the compounds

[0113] The 50 % cytotoxic concentration (CC_{50}) was determined using a protocol adapted from Pauwels et al. (1988. J. Virol. Methods 20(4):309-21). Briefly, flat bottom 96-well plates were filled with 50 μ l of complete medium containing 5×10^3 P4 cells. 2 hours later 50 μ l of drug solution were added to the cells. Drugs (dissolved in

DMEM, see above) were diluted in six, 5-fold serial dilutions from stock solutions in triplicate wells of a 96-well plate. Cells and compounds were incubated at 37°C in growth medium for 3 days. Cell viability was determined by MTT assays using the Roche Cell Proliferation KIT. The absorbance ($\lambda=570\text{nm}$) was measured on a Benchmark™ Microplate Reader (Biorad) and compared with 12 cell control replicates (no drug added). Each assay was performed at least three times for a total of at least nine replicate wells. This method detects both cytostatic and cytolytic effects of drugs.

Anti-HIV assay

[0114] The P4 cells are HIV-infectible Hela-CD4 cells that carry the bacterial *lacZ* gene under the control of the HIV-1 long terminal repeat (LTR). In this cell line, transcription of the *LacZ* gene is driven by the HIV-1 LTR. As such, the cytoplasmic accumulation of β -galactosidase is strictly dependent on the presence of the HIV transactivator Tat produced during the intracellular viral replication (Clavel & Charneau, 1994. J. Virol., Vol.68, p. 1179-1185). In other words, in this system, the expression level of the β -galactosidase gene is proportional to the viral replication.

[0115] Briefly, in the anti-HIV assay 100 μl of P4 cells were plated in 96-well plate at a concentration of 0.4×10^5 cells/ml and incubated at 37°C, 5 % CO_2 . After 48h, the medium was removed and 100 μl of the different drugs dilutions were added to the cells. Four hours after the addition of the drugs all cells were infected with equal amount of cell-free virus, corresponding to 100 ng of HIV p24 antigen. After 48h of incubation at 37°C, 5% CO_2 , β -galactosidase activity was measured using chlorophenol red- β -D-galactopyranoside assays.

[0116] The absorbance was measured on a Benchmark™ Microplate Reader (Biorad) ($\lambda=570\text{nm}$) and compared with 12 cell control replicates (no virus or drug added) and 12 virus control wells (no drug added). Each assay was performed a minimum of three times. The 50 % effective concentration (EC_{50}) was calculated from each dose response curve using the CurveExpert 1.3 software. As Nevirapine activity corresponds to its published values (10-100 nM), the data are consistent with other measures of viral replication.

[0117] The anti-HIV assay with TZM-bl cells is essentially the same as described above with P4 cells. The main difference between the two cell lines is that the TZM-bl cells express at their surface both the CD4 and CCR5 proteins, acting as receptor and co-receptor for HIV entry, respectively (Wei et al. 2002. Antimicrob. Agents Chemother. Vol. 46, p1896-1905). This feature makes the cells very sensitive to infection by the virus. The TMZ-bl cells were infected with equal amount of cell-free virus, corresponding to 10 ng of HIV p24 antigen. This amount is ten times lower than the amount used to infect the P4 cells.

[0118] The MT-4 cells rapidly die upon infection by HIV. In this system there is an inverse correlation between cells survival and the amount of viral replication.

[0119] Briefly, in the anti-HIV assay exponentially growing MT-4 cells were infected with HIV-1. 100 μl of infected MT-4 cells were seeded in 96-well plate at a concentration of $0.4 \cdot 10^5$ cells/ml, and 100 μl of the different drugs dilutions were added to the cells. After 4 days of incubation at 37°C , 5% CO_2 , cells survival was measured using MTS (3-(4-5-dimethylthiazol-2-yl)-5-(-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)

assays. This compound is reduced by viable cells in a colored soluble formazan salt.

[0120] The absorbance was measured on a Benchmark™ Microplate Reader (Biorad) ($\lambda=490\text{nm}$) and compared with 12 cell control replicates (nor virus nor drug added) and 12 virus control wells (no drug added). Each assay was performed a minimum of three times. The 50 % effective concentration (EC_{50}) was calculated from each dose response curve using the CurveExpert 1.3 software.

10 [0121] PBMCs isolated from the blood of healthy donor contain CD4^+ T-lymphocytes which are one of the main targets of HIV in infected individuals.

[0122] Briefly, in the anti-HIV assay PBMCs, activated with phytohemagglutinin, were infected with HIV-1. 100 μl of infected PBMCs were seeded in 96-well plate at a concentration of $1 \cdot 10^5$ cells/ml, and 100 μl of the different drugs dilutions were added to the cells. After 4 days of incubation at 37°C , 5% CO_2 , cells cultures supernatants were collected. The amount of the viral capsid protein p24 in the supernatants was measured using the Innostest HIV Antigen mAb P24 kit (Innogenetics).

[0123] The results of tests are summarized in tables 4 to 7. From tables 4 and 5, it can be derived that the compounds according to the invention have good to excellent EC_{50} values and are able to inhibit HIV-1 activity in several tests performed on various cell lines such as P4, TZM-bl, MT-4 and PBMC. The best compounds (Z150, Z153) display a higher selectivity index (SI) than nevirapine and efavirenz due to their high antiviral activity combined with a low cytotoxicity. The demonstrated low cytotoxicity is a first indication that the compounds could be very useful in the treatment of HIV and especially HIV-1 infected individuals.

[0124] That some of the compounds, for instance Z150, are active on HIV-1 mutant strains resistant to Nevirapine (such as Cys188RT, Cys181RT, Asn103RT) is evident from table 6 and 7.

5

Table 4: *Ex vivo* anti-HIV activity (EC₅₀), cytotoxicity (CC₅₀) and SI (selectivity index = CC₅₀/EC₅₀) for some compounds according to the invention, the test being performed on a P4 cell line with a WT (wild type) RT.

10 Comparison with Nevirapine and Efavirenz, two common RT inhibitors

N°	EC ₅₀ WT (μ M)	CC ₅₀ (μ M)	SI
M18	5.82	>100	>17
Z12	3.09	>100	>32
Z25	0.48	81	168
Z30	0.52	>100	>192
Z32	1.16	55	47
Z33	1.03	54	52
Z37	0.043	58	1349
Z37A	0.24	63	263
Z37B	0.085	72	847
Z37inv	0.036	64	1778
Z45inv	0.023	76	3304
Z54	1.35	58	43
Z57	1.82	ND	ND
Z91inv	<0.001	37.2	>37200
Z114	0.007	8	1143
Z121	<0.001	27	>27000
Z122	0.001	27.5	27500
Z150	<0.001	66	>66000
Z153	<0.001	54	>54000
Z154	<0.001	80	>80000
Nevirapine	0.029	>100	3448
Efavirenz	<0.001	40	>40000

Table 5: *Ex vivo* anti-HIV activity (EC₅₀) for some compounds according to the invention, the test being performed on TZM-bl, MT4 and PBMC cell lines with a WT (wild type) RT. Comparison with Nevirapine and Efavirenz, 5 two common RT inhibitors

N°	EC ₅₀ TZM-bl (μ M)	EC ₅₀ MT4 (μ M)	EC ₅₀ PBMC (μ M)
Z37inv	0.439	ND	0.054
Z45inv	0.197	ND	0.018
Z91inv	<0.001	<0.001	<0.001
Z114	0.011	0.136	<0.001
Z121	ND	0.014	<0.001
Z122	ND	<0.001	<0.001
Z150	<0.001	<0.001	ND
Z153	<0.001	ND	ND
Z154	0.003	<0.001	ND
Z167	<0.001	ND	ND
Nevirapine	0.056	0.575	0.030
Efavirenz	<0.001	<0.001	ND

Table 6: *Ex vivo* anti-HIV activity (EC₅₀) for some compounds according to the invention, the test being performed on P4, TZM-bl or MT4 cell lines with mutant RT characterized by a Cysteine for Tyrosine substitution at codon 188 (Cys188RT) or 181 (Cys181RT) or by a Leucine for Isoleucine substitution at codon 100 (Ile100RT) in the RT. Comparison with Nevirapine and Efavirenz, two common RT inhibitors.

N°	Cys188RT			Cys181RT			Ile100RT	
	P4 (μ M)	TZM-bl (μ M)	MT4 (μ M)	P4 (μ M)	TZM-bl (μ M)	MT4 (μ M)	TZM-bl (μ M)	MT4 (μ M)
Z37inv	0.010	ND	ND	1.97	2.54	ND	ND	ND
Z45inv	0.008	ND	ND	0.496	3.2	ND	0.382	ND
Z91inv	<0.001	ND	0.043	0.046	0.058	2.44	0.002	1.38
Z114	0.003	0.001	1.68	0.087	0.411	Inactive	0.077	Inactive
Z150	<0.001	<0.001	0.006	0.061	0.086	0.32	0.020	0.087
Z153	<0.001	<0.001	0.033	0.108	0.083	0.78	0.029	0.187
Z154	<0.001	ND	ND	ND	0.288	ND	0.040	ND
Z167	ND	<0.001	ND	ND	0.007	ND	ND	ND
Nevirapine	1.635	2.72	>5	10	8.3	Inactive	0.05	2.06
Efavirenz	<0.001	<0.001	0.001	<0.001	<0.001	<0.001	0.017	0.178

Table 7: Ex vivo anti-HIV activity (EC50) for some compounds according to the invention, the test being performed on P4, TZM-bl or MT4 cell lines with mutant RT characterized by a Lysine for Asparagine substitution at codon 103 (Asn103RT), by a Valine for Isoleucine substitution at codon 108 (Ile108RT) or by the double substitution at codon 103 and 108 (Asn103/Ile108RT) in the RT. Comparison with Nevirapine and Efavirenz, two common RT inhibitors:

N°	Asn103RT			Ile108RT		Asn103/ Ile108RT		
	P4 (μ M)	TZM-bl (μ M)	MT4 (μ M)	TZM-bl (μ M)	MT4 (μ M)	P4 (μ M)	TZM-bl (μ M)	MT4 (μ M)
Z37inv	ND	ND	ND	1.09	ND	ND	ND	ND
Z45inv	ND	ND	ND	ND	ND	19.2	ND	ND
Z91inv	0.089	0.355	0.98	<0.001	0.072	0.18	ND	9.9
Z114	0.643	0.584	inactive	0.012	12	1.93	ND	inactive
Z150	ND	0.011	<0.001	0.004	<0.001	0.027	0.158	0.958
Z153	ND	0.042	0.15	0.001	0.008	0.070	0.366	3.48
Z154	ND	0.029	ND	0.014	ND	0.088	0.231	ND
Z167	ND	ND	ND	ND	ND	ND	0.129	ND
Nevirapine	1.71	2.1	>25	0.091	1.27	6.25	ND	inactive
Efavirenz	ND	0.035	0.005	<0.006	<0.001	0.009	0.150	1.19

10

[0125] The compounds according to the present invention could be administrated orally to humans in a dosage range of 1 to 100 mg/kg body weight in divided doses. It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may vary and will depend upon a variety of factors including the activity of the compound employed, its metabolic stability and length of action, as well as the age, the weight and the general health of the patient at the time of the administration, the rate of excretion, the other drugs used, and the host undergoing therapy. It falls

20

within the skills of an artisan to determine the concentration of drugs that should be used in HIV-1 treatment.

[0126] The compounds of the present invention can be
5 used for the preparation of medicaments such as therapeutic compositions for the treatment of HIV-1 related diseases. The compounds can be used alone (in pure form, as salt or as prodrug), or as mixtures of several compounds, whether or not in combination with other compounds active against
10 HIV-1 infections.


[0127] Such anti-viral agents include other NNRTIs such as Nevirapine, Efavirenz, Delavirdine, Capravirine and the like as well as NRTIs, protease inhibitors, fusion/binding inhibitors, integrase inhibitors,
15 pyrophosphate analogue RT inhibitors and/or HIV vaccines. The above list is not exhaustive and may include any other anti-viral, anti-infective, antibiotic as well as any immunomodulator. The effect can be additive and/or synergistic.

20 [0128] The compounds according to the invention and mixtures thereof with any other therapeutic and/or pharmaceutical agent can be used in pharmaceutical compositions comprising an acceptable diluent and/or carrier. These are known to a skilled person.

25 [0129] Administration in the case of combinations can be together or consecutively whereby the interval can range from minutes to hours. It is evident that other applications than oral applications are possible, for instance in the case of combination with a therapeutic
30 and/or prophylactic vaccine. It is further evident that the compounds according to the inventions can be applied under any form that does not preclude their activity, such forms including pills, liquids, powders, pastes and any other form or formulation known in the art.

Example 11: Comparison of some compounds according to the invention with compounds disclosed in prior art and influence of the R2 type on the activity of the compound

[0130] Compounds according to the present invention were compared with compounds known in the art. Provided that any group that is linked to position 4 of the pyridinone ring is hereby referenced as "R2", and X is defined as the "spacer" between the two groups, the following can be concluded



10

[0131] Compounds disclosed in patents EP 0 462 800 and EP 0 481 802 differ by their substitution in position 3 and differ by their substitution in position 4 (no spacer between the pyridinone and R2 in the compounds disclosed in EP 0462 800 and EP 0 481 802 whereas all compounds of the present invention have such a spacer).

[0132] The compounds disclosed in patent EP 0 462 808 differ by their substitution in position 3 (all possess a phthaloyl group on this position). They are further not substituted in position 4.

[0133] The compounds disclosed in WO97/05113 and publication of Dolle differ by their substitution in position 4. Only arylthio and arylamino groups are considered, whereas compounds of the invention do not feature such groups in position 4.

[0134] The compounds disclosed in WO99/55676 differ by their substitution in position 3. Only amino or alkylamino groups have been considered. None of these chemical functions is present in the invention.





[0135] Compounds disclosed in International patent application WO02/24650 are of the above the compounds most closely related with those of the present invention, the compounds having a spacer between the pyridinone ring and

5 R2, the R2 groups may be comparable at first sight. However, the specific compounds disclosed in WO02/24650 to have anti-HIV activity all feature an aryl substituent at position 4 of the pyridinone ring, unlike compounds of the present invention. No compound bearing a C₇₊ cycloalkyl or


10 a substituted cycloalkyl in position 4 is disclosed and/or claimed in International patent application WO02/24650.

[0136] The following table 8 demonstrates the interest of for instance C₇₊ cycloalkyls or substituted cycloalkyls as evident from the EC₅₀ value:

15 Table 8: Effect of the R2 substituent on EC₅₀ values

		
R2	EC ₅₀ WT (μM)	EC ₅₀ Cys188RT (μM)
	1.91	ND
	0.77	6.5
 (formula VII, Z25)	0.48	3.28

43

 (formula II, Z37)	0.043	0.006
--	-------	-------

ND, not determined

[0137] As shown in Table 8, replacement of a cyclopentyl or cyclohexyl by a cycloheptyl leads to an increase in antiviral potency of the compounds.

[0138] Replacement of a cyclohexyl by a m,m-dimethyl-cyclohexyl leads to a 16-fold increase in antiviral potency.


[0139] Furthermore, compounds Z25 and Z37 are more active on Cys188 mutant strains than the cyclohexyl derivative.

[0140] It goes beyond any doubt that the above examples are sufficient to demonstrate that the problem of providing alternative compounds active against HIV-1, with pronounced NNRTI activity, is solved by the compounds according to the invention which are novel and inventive.

[0141] Advantageously, compounds according to the invention can be active against HIV-1 strains that are resistant to NNRTIs currently used such as Nevirapine.

CLAIMS


1. A 5-ethyl-6-methyl-2-pyridinone derivative compound according to general formula I,



(formula I)

5 wherein

X = O, S, NH, C=O, (C_nH_{2n}), (C_nH_{2n})O, O(C_nH_{2n}), (C_nH_{2n})S, S(C_nH_{2n}) with n = 1-4




with n, m = 0 - 8

Ar = Aromatic ring selected from : phenyl, pyridyl, thiazolyl, furanyl, thiophenyl, benzofuranyl, benzothiophenyl, benzothiazolyl, imidazolyl, indolyl,
 each optionally substituted with up to 4 substituents selected from :
 halo, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ hydroxyalkyl, C₁₋₄ alkylamino, amino,
 C₁₋₄ aminoalkyl, C₁₋₄ alkylcarbonyl, C₁₋₄ dialkylamino, azido

Y = alkyl, amino, nitro or

Y = H, halo, alkylamino, dialkylamino, nitrile, hydroxy, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylcarbonyloxy, C₅₋₇ cycloalkyl optionally substituted with up to 4 substituents selected from : halo, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ hydroxyalkyl, C₁₋₄ alkylamino, amino, C₁₋₄ aminoalkyl, C₁₋₄ alkylcarbonyl, C₁₋₄ dialkylamino, azido, nitrile; or Y can be :



R₂ = C₇₋₉ cycloalkyl;

C₅₋₈ cycloalkyl substituted with up to 4 substituents;

C₅₋₈cycloalkenyl optionally substituted with up to 4 substituents;


C₅₋₈aliphatic heterocycle optionally substituted with up to 4 substituents;

C₆₋₉bridged cycloalkyl optionally substituted with up to 4 substituents;


C₆₋₉bridged cycloalkenyl optionally substituted with up to 4 substituents;

substituents selected from :

halo, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ hydroxyalkyl, C₁₋₄ alkylamino, amino, C₁₋₄ aminoalkyl, C₁₋₄ alkylcarbonyl, C₁₋₄ dialkylamino, azido, CN;



Or R2 can be :




$n, m = 0 - 8$

2. The compound according to claim 1 further characterized in that it has a substituted cycloalkyl group as R2 in position 4 of the pyridinone ring.

5 3. The compound according to claim 2 further characterized in that said substituted cycloalkyl group is a 3,5-dimethylcyclohexyl moiety.












4. The compound according to claim 1 further characterized in that it has a C7-9 cycloalkyl group as R2
10 in position 4 of the pyridinone ring.












5. The compound according to claim 1 further characterized in that R2 accords to formula XII





with $n=0 - 8$, preferably $n=0, 1, 2, 3$ or 4 , more
15 preferably $n=0, 1$, or 2 and most preferably $n=1$.


6. The compound according to claim 1
 selected from the groups consisting of M18, Z12, Z25, Z30,
 Z32, Z33, Z37, Z37inv, Z53, Z54, Z55, Z57, Z45inv, Z91inv,
 Z96inv, Z114, Z121, Z122, Z150, Z153, Z154 and Z167,
 5 wherein X, R1 and R2 are as indicated below:

N°	X	R1	R2
M18	O	CO ₂ Et	
Z12	O	CO ₂ Et	
Z25	O	CO ₂ Et	
Z30	O	CO ₂ Et	
Z32	O	CH ₂ OH	
Z33	O		
Z37	O	CO ₂ Et	
Z53	O		
Z54	O	CO ₂ Et	

Z55	O	CO ₂ Et	
Z57		CO ₂ Et	
Z45inv	O	CH ₂ OH	
Z91inv	O	NO ₂	
Z96inv	O	NH ₂	
Z114	O	CH ₂ SCOMe	
Z121	O	CH ₂ S(CH ₂) ₂ OH	
Z122	O	CH ₂ S(CH ₂) ₂ OCOCH ₂ Cl	
Z150	O	NMe ₂	
Z153	O	CH ₂ N ₃	

Z154	O	Me	
Z167	O	Et	

7. A compound (M18) according to claim 1,

with X = O, R1 = CO₂Et and R2 = 

8. A pharmaceutical composition comprising at least one the compounds according to any of claims 1 to 7 and an acceptable carrier and/or diluent.

9. The composition according to claim 8 further comprising another anti-viral agent.

10. The composition according to claim 9, characterized in that said anti-viral agent is Nevirapine.

11. Use of the compound or the composition according to any of the preceding claims 1 to 10 for the preparation of a medicament in the treatment and/or the prevention of HIV-1 infections.

12. The use according to the claim 11 for the preparation of a medicament for the treatment and/or prevention of HIV-1 infections by a strain resistant to at least one anti-viral agent.

13. The use of claim 12 wherein said anti-viral agent is Nevirapine.

14. A method for obtaining an irreversible anti-HIV-1 compound, which method comprises the steps of:


- selecting an anti-HIV-1 compound, preferably a NNRTI, that interacts with a binding site of an HIV-1 enzyme,
- introducing a chemical modification in the structure of said anti-HIV-1 compound that allows the formation

of at least one covalent bond between the compound and an amino acid of said HIV-1 enzyme.


15. The method of claim 14, wherein the HIV I binding site is the allosteric site of HIV I reverse transcriptase.

16. An irreversible NNRTI obtainable by said method.



17. The irreversible NNRTI according to claim 16 which is a compound (Z122) according to formula I with X




1/7

Fig. 1




2/7

Fig. 2AFig. 2B


3/7

Fig. 3


4/7

Fig. 4Fig. 5Fig. 6



5/7

Fig 7

6/7

Fig 8

7/7

Fig 9Fig 10

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
31 March 2005 (31.03.2005)

PCT

(10) International Publication Number
WO 2005/028442 A3

(51) International Patent Classification⁷: **C07D 213/80**,
213/69, A61K 31/4412, A61P 31/18

(21) International Application Number:
PCT/BE2004/000134

(22) International Filing Date:
22 September 2004 (22.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
03447231.6 22 September 2003 (22.09.2003) EP

(71) Applicants (for all designated States except US): **FACULTES UNIVERSITAIRES NOTRE-DAME DE LA PAIX** [BE/BE]; Rue de Bruxelles 61, B-5000 NAMUR (BE). **UNIVERSITE LIBRE DE BRUXELLES** [BE/BE]; Avenue F.D. Roosevelt 50, CP 161, B-1050 BRUSSELS (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LE VAN**, Kiet [BE/BE]; Rue des Cygnes 32, B-1050 BRUSSELS (BE). **GEORGES**, Benoît [BE/BE]; Rue du Facteur 2, B-1348 LOUVAIN-LA-NEUVE (BE). **HEVESI**, Laszlo [BE/BE]; Rue d'Enhaive 18, B-5100 JAMBES (BE). **CAUVIN**, Christine [BE/BE]; Place Notre-Dame de la Paix 2, bte 28, B-5101 ERPENT (BE). **BOLAND**, Sandro [BE/BE]; Rue des Thiers 5, B-4210 BURDINNE (BE). **DURANT**, François [BE/BE]; Allée de Menton 24B, B-5000 NAMUR (BE). **DEMONTE**, Dominique [BE/BE]; Rue en dessous, 13, B-5650 YVES-GOMEZEE (BE). **VAN LINT**, Carine [BE/BE]; Corniche Verte 16, B-1150 BRUSSELS (BE). **BURNY**, Arsène [BE/BE]; Chaussée de Namur 65, B-5030 GEMBLOUX (BE). **BOLLEN**, Alex [BE/BE]; Gaasbeekstraat 69, B-1701 ITTERBEEK (BE). **JACQUET**, Alain [BE/BE]; Service

de génétique appliquée, Rue des Professeurs Jeener et Brachet 12, B-6041 GOSSELIES (BE). **DE WALQUE**, Stéphane [BE/BE]; Rue de Brasserie 13, B-1350 FOLX-LES-CAVES (BE).

(74) Agents: **VAN MALDEREN**, Joëlle et al.; pronovem - Office Van Malderen, Avenue Josse Goffin 158, B-1082 Bruxelles (BE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
9 September 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 2-PYRIDINONE DERIVATIVES, HAVING HIV INHIBITING PROPERTIES

(57) Abstract: The present invention relates to 2-Pyridinone derivatives, more specifically 5-ethyl-6-methyl-2-pyridinone derivatives, according to general formula I that inhibit human immunodeficiency virus type 1 (HIV-1) replication and are therefore of interest in the treatment of Acquired Immune Deficiency Syndrome (AIDS). The present invention further relates to the synthesis of said compounds and their use, with or without other pharmaceutical agents, in the treatment of AIDS and viral infections by HIV-1.



WO 2005/028442 A3

INTERNATIONAL SEARCH REPORT

International application No.
PCT/BE2004/000134

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-13,17

Compounds of formula (I)

2. claims: 14-16

Method for obtaining an irreversible anti-HIV compound

INTERNATIONAL SEARCH REPORT

International Application No

PCT/BE2004/000134

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D213/80 C07D213/69 A61K31/4412 A61P31/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, BEILSTEIN Data, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99/55676 A (AUBERTIN ANNE MARIE ; BISAGNI EMILE (FR); DOLLE VALERIE (FR); GRIERSON) 4 November 1999 (1999-11-04) cited in the application	1,8-13
A	page 1, line 26 - page 3, line 21; claim 1; example 1	2-7,17
X	WO 02/24650 A (JANSSEN PHARMACEUTICA NV ; BENJAHAD ABDELLAH (FR); GUILLEMONT JEROME) 28 March 2002 (2002-03-28) cited in the application	1,8-13
A	page 2, line 4 - page 9, line 20; claim 1; example 69	2-7,17
	----- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

6 July 2005

Date of mailing of the international search report

18.07.05

Name and mailing address of the ISA

European Patent Office, P.O. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Uselli, A

INTERNATIONAL SEARCH REPORT

International Application No

.../BE2004/000134

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DOLLE V ET AL: "A NEW SERIES OF PYRIDINONE DERIVATIVES AS POTENT NON-NUCLEOSIDE HUMAN IMMUNODEFICIENCY VIRUS TYPE U SPECIFIC REVERSE TRANSCRIPTASE INHIBITORS" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 38, no. 23, 15 October 1995 (1995-10-15), pages 4679-4686, XP002002675 ISSN: 0022-2623	1-13,17
X	Scheme 4 tables 1-3	14-16
X	WO 98/37072 A (THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SEC) 27 August 1998 (1998-08-27) page 8, line 1 - page 8, line 9; claim 1	16
X	DOLLE V ET AL: "Synthesis of new non-nucleoside inhibitors of HIV-1" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 6, no. 2, 23 January 1996 (1996-01-23), pages 173-178, XP004135103 ISSN: 0960-894X Scheme 2	14-16

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
i /BE2004/000134

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9955676	A	04-11-1999	AU 4137899 A	16-11-1999
			BG 104984 A	31-07-2001
			BR 9909976 A	26-12-2000
			CA 2330304 A1	04-11-1999
			CN 1303378 A	11-07-2001
			CZ 20003978 A3	12-09-2001
			EE 200000620 A	15-04-2002
			WO 9955676 A1	04-11-1999
			EP 1073637 A1	07-02-2001
			HR 20000716 A1	30-06-2001
			HU 0101595 A2	28-11-2001
			ID 27502 A	12-04-2001
			JP 2002513004 T	08-05-2002
			MX PA00010490 A	17-10-2002
			NO 20005387 A	04-12-2000
			NZ 508297 A	20-12-2002
			PL 343685 A1	27-08-2001
			SK 16072000 A3	04-04-2002
			TR 200003113 T2	21-05-2001
			US 2003125340 A1	03-07-2003
			US 6451822 B1	17-09-2002
			ZA 200006037 A	25-01-2002
WO 0224650	A	28-03-2002	AU 1259802 A	02-04-2002
			EP 1318995 A2	18-06-2003
			WO 0224650 A2	28-03-2002
			JP 2004509867 T	02-04-2004
			US 2004229847 A1	18-11-2004
WO 9837072	A	27-08-1998	AT 238998 T	15-05-2003
			AU 741772 B2	06-12-2001
			AU 6337198 A	09-09-1998
			CA 2281927 A1	27-08-1998
			DE 69814049 D1	05-06-2003
			DE 69814049 T2	19-02-2004
			EP 0963371 A1	15-12-1999
			JP 2001513084 T	28-08-2001
			WO 9837072 A1	27-08-1998
			US 2003191160 A1	09-10-2003
			US 6369235 B1	09-04-2002